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The association of T lymphocytes and dendritic cells 
with the stromal mononuclear cell response to basal cell 
carcinomas has led to speculation that cellular immunity 
may, in part, regulate the growth and development of 
this neoplasm. It has not been established, however, 
whether these T cells are functionally competent, or 
simply coincidental bystanders. We examined the im-
munologic phenotypes of mononuclear cells in 32 lesions 
of basal cell carcinoma obtained from 26 patients. The 
majority of infiltrating mononuclear cells were T cells 
that were equally distributed between the helper/in-
ducer (Leu 3a+) and cytotoxic/suppressor (Leu 2a+) sub-
types; a minority of cells were dendritic and expressed 
Leu 6 antigen. Virtually all T cells and dendritic cells 
were HLA-DR+, and many (>30 %) of the T cells ex-
pressed antigens consistent with stages of ongoing acti-
vation (T9, T10). TS2/7, a novel monoclonal antibody 
recently documented to identify activation-specific sub-
components of 210/165/130 kD glycoprotein complex 
present on the surface of mitogen- or alloantigen-stim-
ulated human T cells, was also used. Greater than 50% 
of the T cells observed were TS2/7+. These observations 
provide in situ immunomorphologic evidence of stromal 
T cell activation in association with basal cell carcino-
mas, and suggest a role for active and ongoing cellular 
immune mechanisms as a determinant of local biological 
behavior of this neoplasm. 
A number of recent studies have focused on the in s itu 
association of various subsets of lymphocytes, identified by 
immunologic methods, with cuta neous alterations typical of a 
variety of inflammatory dermatoses and cutaneous neoplasms 
[1-5]. The immunologic phenotypes of t hese cell s (e.g., helper/ 
inducer subset) provide litt le information , however, concerning 
t heir actual-state func t ional compete ncy [6- 9]. Recently, 
monoclonal antibodies have been developed t hat defin e glyco-
proteins essentially restricted, at extra t hymic sites, to activated 
T cells [10]. Detection of these activat ion antigens may be 
expected to provide insight into t he functional capacity and 
responsiveness of mononuclear ce lls infiltrating the skin. 
The role of local cellular immunity in basal cell carcinoma 
has been t he subject of seve ra l recent investigations [11- 14]. 
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Mononuclear cell infiltrates associated with t hese neoplasms 
are comprised predominantly ofT cells [11] that are associated 
with Langerhans cells in a manner ak in to t hat observed in 
delayed-hypersensi t ivity responses [12,13]. Indeed, it has been 
suggested that tumor-specific antigens may be instrumental in 
inciting these cellular infiltrates [1 4]. These studies have been 
limited , however , by inclusion of relatively small patient pop-
ulations. Moreover, detailed assessment of the state of func-
tional activation of these infiltrating T cells has not been 
performed. 
In order to determine whether T cells associated with basal 
cell carcinomas express activation an t igen s, we studied 32 
lesions from 26 patients with a panel of monoclonal an tibodies, 
including OKT9, OKT10, a nd TS2/7. OKT9 recognizes t he 
transferrin receptor [ 15, 16] of proliferating cells, and has been 
shown to identify T cells in early phases of activation, before 
t he onset of DNA synthesis [6]. OKT10 recognizes a 46 kD 
antigen [ 15,17] that is expressed during the intermediate stage 
ofT -cell activation [6]. TS2/7 is a newly described monoclonal 
antibody that reacts only with activation-specific subcompo-
nents of a glycoprotein complex (A-1A5) found on the surfaces 
of mi togen- or a lloan t igen-stimulated T cells [10,18]. Our data 
suggest t hat many T cells ch aracterist ic of t he inflammatory 
infil t rates of basal cell carcinomas express activation an tigens 
and therefore are likely to be participants in an ongoing local 
cuta neous immune response. The potential significance of these 
observations in regard to t he indolent biologic behavior of these 
neoplasms is discussed. 
MATERIALS AND METHODS 
Patient Popu.lation 
Thirty-two excisions were obtained from 26 patients who presented 
for dermatologic evaluat ion as outpatients. All specimens were obtained 
from sun -exposed sites and all patients had historical evidence of long-
standing sun exposure. No patients had pigmentary abnormalit ies, 
evidence of basal cell nevus syndrome, or overt immunologic abnor-
mali ties. Detailed clinical questionnaires were maintained and included 
information relevant to skin type, sun exposure, and biologic aggres-
siveness of lesions (size, ulceration, rapidi ty of growth). Clinical pho-
tographs were obtained in the majori ty of patients. Specimens were 
froze n immediately in OCT (Optimal Cutting Temperature; Lab-Tek, 
Division of Miles Laboratories, Naperville, Illinois) and subsequently 
sectioned on a cryostat for diagnostic evaluation and immunohisto-
chemica l stain ing. 
Monoclonal Antibodies 
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The monoclonal antibodies Leu 2a, Leu 3a, and ant i-HLA-DR. 
(Becton Dickenson, Mountain View, California) were used for routine 
immunop henotyping. Leu 2a reacts with T lymphocytes of the cyto-
toxic/suppressor subset, Leu 3a reacts with T lymphocytes of the 
helper/ inducer subset, Leu 6 reacts with Langerhans cells and indeter-
minate cells [19,20 ] but not with peripheral T cells, and ant i-HLA-DR 
reacts with the nonpolymorphic region of human !a-l ike antigens. In 
addi t ion, OKT9, OKT10 (Ortho Pharmaceutical, Raritan, New Jersey), 
and TS2/7 (courtesy of Steven J. Burakoff, M.D.) , were used to assess 
stages of T -cell activation in 7 specimens. OKT9 reacts with the 
transferrin receptor [1 5,16] and is first observed during early stages of 
T-cell activation [6], OKT10 identifies T cells in intermediate stages 
of proliferation and activation [6], and TS2/7 [10] specifically identifies 
mi togen- and alloantigen-stimulated T cells during late stages of their 
activation. 
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Jm.m u.nohistochem islly 
T he technique employed primary monoclonal ant ibodies, a biotiny-
Jated secondary antibody, and an avidin -biotin -horseradish peroxidase 
complex (Vector Laboratories Inc., Burlingame, California). This tech-
nique has been desc ribed previously in detail [21]. All sections were 
stained with 3,3' -diaminobenzidine (DAB) (Sigma, St. Louis, Missouri) 
for 60 s and rinsed in phosphate- buffered saline to terminate the 
sta ining reaction. Sections were counterstained lightly with methyl 
green prior to observation by light. microscopy. 
Quantification of Positive Cells 
Because some va riabili ty resul ted from regional differences in adja-
ce nt sections of tissue, rel at ive ce ll numbers were determined semi-
quantitatively as percentages of total mononuclear ce ll number. Enu-
meration of positively labeled cells were facilitated by the use of an 
ocular grid micrometer. 
RESULTS 
Clinica lly, 5 cases were biologically aggressive (large, rapidly 
growing lesions). There was not correlation, however, between 
histology , including mitotic rate, or immunohi stochemical 
staining patterns and clinical parameters of biologic aggres-
siveness or of duration of les ions. Histologic eva luation revealed 
a ll lesions to be invasive basal cell carcinomas. Although some 
a lso ·showed associated multipl e superficial foci within the 
epidermis, sclerosing or anaplastic (metatypical) variants were 
not observed. 
The majority (>90%) of mononuclea r cells in the stromal 
infiltrates were reactive with either anti-Leu 2a or anti-Leu 3a 
antibodies. On the average , approximately 50% were Leu 2a+ 
and 50% were Leu 3a+, with a range of 40- 60% in individua l 
cases (Fig lA ,B) . All of these cells expressed HLA-DR antigen 
(Fig l C), as dete rmin ed by qua ntitative evaluation of adjacent 
sections. T cell s were int imately assoc iated with tumor cell s 
comprising bot h invasive nests a nd mul t iple superficial foci. 
Infil tration of tumor nests by T cells was foca lly observed, 
pa rt icularly by cells of the Leu 2a+ phenotype. Leu 6+ / HLA-
DR+ dendritic ce lls were present in normal to apparently in-
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creased numbers within t he perilesional epidermis. Similar 
numbers of dendritic cells were present within t he tumor 
stroma and t he tumor nests (Fig lD ). The dendrites of these 
cell s frequently were elaborate and surrounded adjacent epithe-
lial cells, forming an apparent intercellular staining pattern 
focally within the epidermis and tumor nests (Fig lE). 
Discrete foci of OKT9- and OKTlO-positive mononuclear 
cell s were observed in the stromal infiltrates. These cells often 
comprised >30% of the mononuclear cells in these regions and 
were associated with tumor nests (Fig 2A,C) , but not wi th 
perilesional epidermis. Basal cell carcinoma cells at t he periph-
ery of invasive nests a lso stained wi th OKT9 (Fig 28 ). Variable 
staining of mononuclear cells with TS2/7 was observed, and 
TS2/7+ cells comprised >50% of numerous stromal foci (Fig 
2D). In addition , stain ing of vessel walls and smooth muscle 
as previously reported [7), was also observed. This pattern of 
reactivity facilitated the morphologic definition of the vascular 
stroma characteristic of basal cell carcinoma and of adjacent 
normal skin (report in preparation) . 
DISCUSSION 
We have demonstrated that subpopulations of stromal T 
cells associated with basal cell carcinomas express antigens 
indicative of various stages of their function a l activation. These 
data extend previous observations of immunologic phenotypes 
of mononuclear cells infil trating these neoplasms [11 ,14], and 
provide add itiona l evidence for an ongoing local immune re-
sponse. 
Basal cell carcinomas a re characterized by relatively indolent 
growth, and only rarely metastasize [22] . Aggressive biologic 
behavior appears to be related to size and growth characteristics 
of lesions, or defects in immunologic status in certain individ-
uals [23,24]. Defective local immunosurveillance has been sug-
gested to play a role in t he genesis of these tumors in young 
individua ls prone to multiple lesions [25]. In addition, morpho-
logic and immunohistochemical studies have documented the 
association of activated lymphoid cells with cutaneous tumors 
FIG l. A, Leu 3a; B, Leu 2a; and C, 
l-ILA-OR-positive mononuclear cells as-
sociated with basal cell carcinoma 
(B CC). Note migration of Leu 2a+ cells 
into tumor (B, arrowhead). D , Dendritic 
Leu 6+ cells within tumor stroma and 
infiltrating tumor nests (arrowheads). 
The highly dendritic nature of these cells 
focally produce an intercellular staining 
pattern (£). (A -C, x 400; D, X 800; E, 
X 1000). 
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that may be characterized by clinical regression , such as ma lig-
nant melanoma [4,26]. It is reasonable to hypothesize that if T 
cells are involved in a chronic response to local cuta neous 
(tumor-related) antigens, they would cycle asynch'ronously at 
various stages of functi ona l activation. Such functional sub-
populations wou ld express glycoproteins common to many ac-
t ivated T cell s (e.g., HLA-DR), and smaller proportions of ce lls 
would demonstrate ma rkers for specific phases (early, inter-
mediate, and late stages) of activation. Our findings are in 
keeping with this notion, and provide the first evidence, to our 
know ledge , of the ex istence of various stages ofT -cell activation 
in inflammatory infiltrates assoc iated with basal cell carcino-
mas. It is reaso nable that such cell s may play a role in a chronic 
immunologic response to a slowly evolving tumor such as basal 
ce ll carcinoma. 
It is important to recognize t hat establishment of T -cell 
subtypes has little meaning if t hese cells do not also show 
ev idence of ongoing fun ctional activation. The use of monoclo-
nal antibodies such as OKT9, OKTlO, a nd TS2/7 should faci l-
itate t he study of activation profiles of cutaneous T -ce ll infil -
trates in a variety of disorders. TS2/7 appears to be a marker 
fo r long-term activation of T cell s. This antibody is reactive 
on ly with T cells among activated hematopoietic cells, and 
t herefore is more spec ific forT -ce ll activation t han monoclonal 
antibodies such as OKT9 and HLA-DR. T his specificity is 
similar to that of the interleukin 2 (IL-2) receptor. The level 
of t h e IL-2 receptor antigen , however, has been reported to 
diminish contemporaneously with the expression of TS2/7 
antigen [10], and the latter may t herefore represent an even 
more sensitive probe for T cell -spec ific activation. 
T cells expressing activation antigens were often in close 
proximity to tumor nests, and were assoc iated with T6+ and 
HLA-DR+ dendritic cell s. The epithelial cells s ituated at the 
periphery of many tumor nests showed reactivity for OKT9, 
suggesting that these cells may be predominantly responsible 
fo r growth and proli feration within these nests. 
The precise role of activated T ce lls in t he biologic behavior 
of cu t aneous tumors cannot be dete rmined from this study. In 
vi tro assays ex ist, howeve r, for t he measurement of specific 
alloantigen-like and mitoge nic stimulatory effects of normal 
and n eoplastic ce ll s on subsets of mononuclea r cell s [27]. 
Likewise, assays fo r effects of these mononuclear cell s on 
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FIG 2. A, Clusters of T9+ mononu-
clear ce lls associated with dermal nests 
of tumor (BCC). B, Cells at the periphery 
of tumor nests (arrowheads) also were 
T9 .... C, Stromal aggregates of TlO+ cells 
(asterisks indicate separation artifact ad-
jacent to tumor nest). D, Stromal aggre-
gates of TS2/ 7+ mononuclear ce lls. (A 
and C, X 400; Band D, X 800). 
cultured tumor cell lines have recently been described [27,28). 
Use of t hese techniques is necessary to establish the precise 
nature of the interaction between activated T ce lls and the 
neoplastic cells composing cutaneous tumors. 
In summary, we desc ribe the presence of several activation 
antigens on T cells composing the inflammatory infiltrates of 
basal cell carcinomas. It is suggested that t hese functionally 
activated cells , along with similarly responsive dendritic anti-
gen-presenting cells, may in part be responsible for the indolent 
clinical behavior of these tumors. Further in situ studies in 
immunocompromised hosts prone to t he development of mul-
tiple and aggressive basal cell carcinomas, and in vitro inves-
tigations using models to assess T cell/tumor cell interactions, 
are indicated to further elucidate t he role of local immunity in 
these neoplasms. 
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